Table 4 Logistic analysis of the association of gene polymorphisms and clopidogrel response

CYP2C19*2

*1/*1, n (%)

52 (57.8)

64 (43.0)

1.0 (ref)

N/A

*1/*2, n (%)

37 (41.1)

74 (49.7)

1.625 (0.949–2.783)

0.076

*2/*2, n (%)

1 (1.1)

11 (7.4)

8.938 (1.117–71.509)

0.015

Carriers of *2

38 (42.2)

85 (57.0)

1.817 (1.070–3.086)

0.026

CYP2C19*3

*1/*1, n (%)

81 (93.1)

127 (88.2)

1.0 (ref)

N/A

*1/*3, n (%)

6 (6.9)

17 (11.)

1.807 (0.684–4.774)

0.227

CYP2C19*2 and *3

*1/*1, n (%)

46 (52.9)

53 (36.8)

1.0 (ref)

N/A

*1/*2 + *1/*3, n (%)

7 (8.0)

2 (1.4)

0.248 (0.049–1.253)

0.072

*2/*2 + *1/*3, n (%)

0 (0.0)

0 (0.0)

4.509 (1.387–14.660)

0.012

Carriers of *2 or *3, n (%)

7 (8.0)

2 (1.4)

0.248 (0.049–1.253)

0.072

P2RY12 rs6809699

CC, n (%)

74 (86.0)

107 (75.9)

1.0 (ref)

N/A

CA, n (%)

12 (14.0)

30 (21.3)

1.729 (0.831–3.595)

0.140

AA, n (%)

0 (0)

4 (2.8)

N/A

0.099

CA + AA, n (%)

12 (14.0)

35 (24.1)

2.017 (0.982–4.142)

0.053

APBB1IP rs11015149

CC, n (%)

73 (84.9)

117 (80.1)

1.0 (ref)

N/A

CA, n (%)

10 (11.6)

29 (19.9)

1.809 (0.833–3.931)

0.130

AA, n (%)

3 (3.5)

0 (0)

N/A

0.030

CA + AA, n (%)

13 (15.1)

29 (19.9)

1.392 (0.680–2.850)

0.364